{"paper_id":"df22c956-1b47-4c5a-aaf0-abfc0ce205cd","body_text":"Abstract\nSynchronous endometrial and ovarian carcinomas (SEOCs) that share the same endometrioid histology are generally considered as the result of metastatic spread from one organ to another. However, SEOCs with different histologies are regarded as distinct primary lesions that arise independently from each other. This study was undertaken to compare the mutational landscape of SEOCs with different histologies to confirm or refute the hypothesis of an independent origin. Four patients with synchronous uterine endometrioid carcinoma (UEMC) and ovarian clear cell carcinoma (OCCC) were examined. UEMCs were accompanied by endometrial hyperplasia/endometrioid intraepithelial neoplasia, whereas endometriosis was evident in two cases. Paired UEMC and OCCC specimens were subjected to mutation analysis with massively parallel sequencing. Surprisingly, we found that 50% (2/4) of paired SEOCs with different histologies shared the same somatic mutations, some of which localized in cancer driver genes. Clonality analyses indicated that these tumors were clonally related to each other. Notably, 75% (3/4) of the study patients had Lynch syndrome. The cancer-specific survival figures of patients with synchronous UEMCs and OCCCs were more favorable than those observed in a historical cohort of patients with isolated stage 2/3 OCCCs. Taken together, we set forth a potential explanation that considers clonally related SEOCs as a result of “precursor escape” — whereby precursor cells of endometrial cancer spread beyond the uterus to reach the pelvis and eventually evolve into an OCCC under an increasing mutational burden.\nKey messages\n• SEOCs characterized by different histologies are rare.\n• All cases of SEOCs were accompanied by endometrial hyperplasia.\n• Fifty percent of SEOCs were clonally related to each other.\n• Shared mutations in cancer driver genes were evident among SEOCs.\n• Clonally related SEOCs may be a result of “precursor escape.”\n• Lynch syndrome is highly prevalent in patients with UEMC and synchronous OCCC.\n• The prognosis of synchronous UEMC and OCCC was favorable.\nSimilar content being viewed by others\nReferences\nAlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A, Podratz KC, Bakkum-Gamez JN (2012) Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. Gynecol Oncol 125:109–113\nAnglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, Mackenzie R, Grewal DS, Li-Chang H, Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG (2016) Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst 108:djv428\nSchultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, Perez Mies B, Soslow RA, Lim RS, Viale A, Huberman KH, Palacios JC, Reis-Filho JS, Matias-Guiu X, Weigelt B (2016) Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst 108:djv427\nChao A, Wu RC, Jung SM, Lee YS, Chen SJ, Lu YL, Tsai CL, Lin CY, Tang YH, Chen MY, Huang HJ, Chou HH, Huang KG, Chang TC, Wang TH, Lai CH (2016) Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology. Gynecol Oncol 143:60–67\nSoong TR, Howitt BE, Miron A, Horowitz NS, Campbell F, Feltmate CM, Muto MG, Berkowitz RS, Nucci MR, Xian W, Crum CP (2018) Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas. J Pathol 246:344–351\nSoong TR, Kolin DL, Teschan NJ, Crum CP (2018) Back to the future? The fallopian tube, precursor escape and a dualistic model of high-grade serous carcinogenesis. Cancers (Basel) 10\nSoong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP (2019) The fallopian tube, \"precursor escape\" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol 152:426–433\nChao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, Yang LY, Lin CT, Huang HJ, Chou HH, Liou JD, Chen SJ, Wang TH, Lai CH (2016) Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 7:85529–85541\nmc3.v0.2.8.PUBLIC.maf. https://gdc.cancer.gov/about-data/publications/pancanatlas. Accessed 2020/12/07\nOstrovnaya I, Mauguen A, Seshan VE, Begg CB (2020) Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. Biometrics.\nBerek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J gynaecol Obstetr 143(Suppl 2):59–78\nAmant F, Mirza MR, Koskas M, Creutzberg CL (2018) Cancer of the corpus uteri. Int J gynaecol Obstetr 143(Suppl 2):37–50\nKu FC, Wu RC, Yang LY, Tang YH, Chang WY, Yang JE, Wang CC, Jung SM, Lin CT, Chang TC, Chao A, Lai CH (2018) Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: results from a single-center Taiwanese study. J Formos Med Assoc 117:117–125\nNetwork NCC. NCCN Clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer version 3. 2019-November 26, 2019 ed: NCCN.org; 2019.\nAyhan A, Guvenal T, Coskun F, Basaran M, Salman MC (2003) Survival and prognostic factors in patients with synchronous ovarian and endometrial cancers and endometrial cancers metastatic to the ovaries. Eur J Gynaecol Oncol 24:171–174\nLheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet. 393:1240–1253\nChao A, Lai CH, Wang TH, Jung SM, Lee YS, Chang WY, Yang LY, Ku FC, Huang HJ, Chao AS, Wang CJ, Chang TC, Wu RC (2018) Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. J Mol Med (Berl) 96:527–536\nKolin DL, Dinulescu DM, Crum CP (2018) Origin of clear cell carcinoma: nature or nurture? J Pathol 244:131–134\nKurman RJ, Shih Ie M (2016) The dualistic model of ovarian carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol 186:733–747\nAnglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noe M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM (2017) Cancer-associated mutations in endometriosis without cancer. N Engl J Med 376:1835–1848\nLac V, Verhoef L, Aguirre-Hernandez R, Nazeran TM, Tessier-Cloutier B, Praetorius T, Orr NL, Noga H, Lum A, Khattra J, Prentice LM, Co D, Kobel M, Mijatovic V, Lee AF, Pasternak J, Bleeker MC, Kramer B, Brucker SY, Kommoss F, Kommoss S, Horlings HM, Yong PJ, Huntsman DG, Anglesio MS (2019) Iatrogenic endometriosis harbors somatic cancer-driver mutations. Hum Reprod 34:69–78\nAnglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, Karnezis AN, Marra MA, Yong PJ, Hirst M, Gilks B, Shah SP, Huntsman DG (2015) Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 236:201–209\nGarg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA (2009) Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 33:925–933\nTakeda T, Banno K, Yanokura M, Anko M, Kobayashi A, Sera A, Takahashi T, Adachi M, Kobayashi Y, Hayashi S, Nomura H, Hirasawa A, Tominaga E, Aoki D (2018) Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: a case report. Mol Clin Oncol 9:479–484\nGarg K, Soslow RA (2009) Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 62:679–684\nKobayashi Y, Nakamura K, Nomura H, Banno K, Irie H, Adachi M, Iida M, Umene K, Nogami Y, Masuda K, Kisu I, Ueki A, Yamagami W, Kataoka F, Hirasawa A, Tominaga E, Susumu N, Aoki D (2015) Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers. Int J Gynecol Cancer 25:440–446\nKim MK, Song SY, Do IG, Kim SH, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG (2011) Synchronous gynecologic malignancy and preliminary results of Lynch syndrome. J Gynecol Oncol 22:233–238\nSoliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH (2005) Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol 23:9344–9350\nVogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science. 339:1546–1558\nAcknowledgements\nWe are grateful to Wei-Yang Chang and Jung-Erh Yang for their excellent technical assistance. We thank the members of the Division of Gynecology Oncology for their invaluable help with patient care. The authors acknowledge the statistical assistance provided by the Clinical Trial Center, Chang Gung Memorial Hospital, Linkou, Taiwan — which is funded by the Ministry of Health and Welfare of Taiwan (grant MOHW109-TDU-B-212-114005).\nFunding\nThis study was financially supported by grants (CMRPG3H0353, CMRPG3J0411/3J0401, CRRPG3F0041/2/3, CMRPG3H1151/2) from the Chang Gung Foundation and the Ministry of Science and Technology (106-2314-B-182-053-MY2 and MOST108-2320-B-182-036-MY3).\nAuthor information\nAuthors and Affiliations\nContributions\nConceptualization: [Ren-Chin Wu, Angel Chao], Methodology: [Cindy Hsuan Weng, Chin-Jung Wang, Hung-Hsueh Chou, An-Shine Chao, Chyong-Huey Lai], Formal analysis and investigation: [Ren-Chin Wu, Shu-Jen Chen, Hua-Chien Chen, Kien Thiam Tan, Yun-Shien Lee, Shih-Sin Huang, Lan-Yan Yang], Writing — original draft preparation: [Cindy Hsuan Weng, Ren-Chin Wu, Angel Chao]; Writing — review and editing: [Cindy Hsuan Weng, Ren-Chin Wu, Angel Chao], Funding acquisition: [Ren-Chin Wu, Angel Chao], Resources: [Shu-Jen Chen, Hua-Chien Chen, Kien Thiam Tan], Supervision: [Chyong-Huey Lai]\nCorresponding authors\nEthics declarations\nEthics approval and consent to participate\nEthical approval was granted by the Institutional Review Board (IRB) of Chang Gung Memorial Hospital (IRB No. 201601562B0). Owing to the retrospective nature of the study, the IRB waived the need for written informed consent for retrieval of formalin-fixed paraffin-embedded tissues.\nConsent for publication\nNot applicable.\nConflict of interest\nShu-Jen Chen, Hua-Chien Chen, and Kien Thiam Tan are employees of ACT Genomics, Co. Ltd. All other authors have no conflicts of interest to declare.\nAdditional information\nPublisher’s note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nSupplementary Information\nESM 1 (download XLSX )\n(XLSX 43 kb)\nRights and permissions\nAbout this article\nCite this article\nWeng, C.H., Wu, RC., Chen, SJ. et al. Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of “precursor escape”?. J Mol Med 99, 959–966 (2021). https://doi.org/10.1007/s00109-021-02064-4\nReceived:\nRevised:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00109-021-02064-4","source_license":"public-domain-us","license_restricted":false}